Precision BioSciences to Report Second Quarter 2021 Financial Results on August 12, 2021
Precision BioSciences, Inc. (Nasdaq: DTIL) is set to release its financial results for Q2 2021 and provide a business update on August 12, 2021. The company focuses on developing allogeneic CAR T therapies and in vivo gene correction therapies through its proprietary ARCUS® genome editing platform. Designed for therapeutic safety and effectiveness, ARCUS underpins Precision's pipeline, which includes various CAR T immunotherapy candidates and in vivo gene correction therapies aimed at tackling genetic and infectious diseases.
- Developing multiple CAR T immunotherapy clinical candidates.
- Proprietary ARCUS genome editing platform designed for safety and effectiveness.
- None.
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will publish financial results for the second quarter 2021 and provide a business update on August 12, 2021.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005032/en/
FAQ
When will Precision BioSciences publish its Q2 2021 financial results?
What does Precision BioSciences focus on?
What is the stock symbol for Precision BioSciences?
